Biberach an der Riss, Germany

Christofer Siegfried Tautermann

USPTO Granted Patents = 8 

 

 

Average Co-Inventor Count = 8.5

ph-index = 3

Forward Citations = 28(Granted Patents)


Location History:

  • Biberach, DE (2014 - 2023)
  • Biberach an der Riss, DE (2023 - 2024)

Company Filing History:


Years Active: 2014-2025

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovations of Christofer Siegfried Tautermann

Introduction:

Christofer Siegfried Tautermann, a prolific inventor based in Biberach an der Riss, Germany, has made significant contributions to the field of pharmaceuticals with a total of 6 patents under his name.

Latest Patents:

Among his latest patents is the groundbreaking invention of Cyclopentathiophene carboxamide derivatives as platelet-activating factor receptor antagonists. These compounds have shown promise in treating diseases influenced by antagonizing the activity mediated by the platelet-activating factor receptor. Additionally, Tautermann's work on CCR2 receptor antagonists showcases novel approaches in treating pulmonary diseases such as asthma and COPD.

Career Highlights:

Tautermann has lent his expertise to esteemed companies such as Centrexion Therapeutics Corporation and Boehringer Ingelheim International GmbH, where he has demonstrated his proficiency in drug discovery and development.

Collaborations:

Throughout his career, Tautermann has collaborated with talented individuals in the field, including notable coworkers like Heiner Ebel and Sara Frattini, contributing to a diverse and innovative work environment.

Conclusion:

In conclusion, Christofer Siegfried Tautermann's dedication to innovation in pharmaceuticals has resulted in impactful patents that have the potential to significantly improve the treatment of various diseases. His collaborations and career highlights underscore his commitment to advancing the field of medicine through inventive solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…